Cortex Pharmaceuticals, Inc. (NYSE Alternext US (COR)) President and CEO, Mark A. Varney, PhD, will speak at the 21st Annual Roth Capital Partners Growth Stock Conference to be held at The Ritz-Carlton, Laguna Niguel hotel located in Dana Point, California. Dr. Varney will present on Monday, February 16, 2009, at 1:40 pm PST (4:40 pm EST). The conference will feature executives from approximately two hundred growth companies across a broad spectrum of sectors, including technology, healthcare, financial services, and consumer products.

Dr. Varney will provide a comprehensive update on Cortex�s 2009 corporate objectives and milestones, including recent progress on its lead low impact AMPAKINE� product candidates, CX717 and CX1739 as novel drug therapies for sleep apnea, respiratory depression, and ADHD, as well as on other scientific and corporate developments.

Cortex is planning to initiate a clinical trial in sleep apnea with CX1739 this month. Sleep apnea, which affects approximately 17 million people in North America alone, is a condition that results in repeated cessation of breathing (apneas) that can result in severely reduced blood oxygen levels throughout the night. Chronic under-oxygenation of the blood night-after-night due to sleep apnea is very stressful to many tissues, including the brain and cardiovascular system, and is associated with very serious sequelae such as stroke, hypertension, myocardial infarction, and diabetes. While a device therapy (CPAP) is available, patient compliance is a major problem. Currently no pharmacological agents are available for treatment of sleep apnea, so oral CX1739, if proven safe and effective, could represent a major therapeutic advance and fill a large, unmet medical need.

A live webcast of the presentation can be accessed by logging onto http://wsw.com/webcast/roth20/cor/. A replay will be available for thirty days following the conference.

More information regarding the conference can be found at http://www.roth.com/main/Page.aspx?PageID=7214.

About Cortex

Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for treating psychiatric disorders, neurological diseases and brain-mediated breathing disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE� compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer�s disease. Weak connections in a different part of the brain can result in a slowing down and cessation of breathing, particularly in the presence of opioid analgesic medicines. Such effects can be prevented by AMPAKINE molecules. Many psychiatric disorders occur as a result of imbalances in the brain�s neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. For additional information regarding Cortex, please visit Cortex Pharmaceuticals� Website at http://www.cortexpharm.com.

For more news and information on�Cortex Pharmaceuticals, please visit http://www.IRGnews.com/coi/cor where you can find a video, a fact sheet on the company, investor presentations, and more.

Forward-Looking Statement

Note � This press release contains forward-looking statements concerning the Company�s research and development activities. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. The success of such activities depends on a number of factors, including the risks that the Company�s proposed products may at any time be found to be unsafe or ineffective for any or all of their proposed indications; that patents may not issue from the Company�s patent applications; that competitors may challenge or design around the Company�s patents or develop competing technologies; that the Company may have insufficient resources to undertake proposed clinical studies; and that preclinical or clinical studies may at any point be suspended, fail, or take substantially longer than anticipated to complete. As discussed in the Company�s Securities and Exchange Commission filings, the Company�s proposed products will require additional research, lengthy and costly preclinical and clinical testing and regulatory approval. AMPAKINE compounds are investigational drugs and have not been approved for the treatment of any disease. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this press release. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Cortex Pharm (AMEX:COR)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025 Haga Click aquí para más Gráficas Cortex Pharm.
Cortex Pharm (AMEX:COR)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025 Haga Click aquí para más Gráficas Cortex Pharm.